MétaCan
Menu
Back to cohort
Record W4405054054 · doi:10.1182/blood-2024-209411

Real World Outcomes in Adult Histiocytosis: 23-Year Canadian Single Center Analysis

2024· article· en· W4405054054 on OpenAlexaffabout
Rintu Sharma, Alfredo H. De La Torre, Umberto Falcone, Eshetu G. Atenafu, Harjot Vohra, Jan Delabie, Michael Crump, Vishal Kukreti

Bibliographic record

VenueBlood · 2024
Typearticle
Languageen
FieldImmunology and Microbiology
TopicMast cells and histamine
Canadian institutionsUniversity of TorontoQueen Elizabeth II Health Sciences CentrePrincess Margaret Cancer CentreUniversity Health Network
Fundersnot available
KeywordsMedicineCenter (category theory)Pediatrics

Abstract

fetched live from OpenAlex

Background: Adult histiocytic disorders are rare. Existing knowledge has largely been extrapolated from the pediatric counterparts. Langerhans Cell Histiocytosis (LCH), Erdheim Chester Disease (ECD) and Rosai-Dorfman Disease (RDD) are three most encountered histiocytic disorders. This study aimed to address the paucity of data on the clinical findings and outcomes in adult histiocytic disorders. Methods: Using REB approved Princess Margaret Cancer Center database, we did a retrospective analysis on adult patients (aged >18 years) with histiocytic disorders presenting to our center from January 2000 to June 2023. Results: We identified 96 patients with various primary adult histiocytic disorders. Median age was 45.5 (range 18-80) years; 54 (56%) were males. LCH constituted the majority at 62% (n=60), followed by RDD 20% (n=19), ECD 11% (n=11) and non-LCH histiocytosis 7% (n=6) patients. Unisystem involvement occurred in 34 (57%) LCH patients; isolated bone in 18 (30%), primary pulmonary LCH in 9 patients (15%), isolated skin/subcutaneous in 3 (5%) and, lymph node in 1 patient. Multisystem LCH occurred in 26 (43%) patients; >2 organ systems were involved in 11 (18%) patients. Sixteen patients (27%) patients had high-risk organ (HRO) involvement defined as involvement of spleen, liver, CNS, or bone marrow. Twelve (20%) patients had CNS involvement; diabetes insipidus in 11 (18%) patients. History of smoking was significantly elicited in patients with LCH compared to ECH or RDD. (67% vs 13% vs 16%; p<0.0001). Although BRAF V600E positivity was low (28%; available in 36 patients) in our cohort, it was equally distributed amongst unisystem (33%) and multisystem (24%) disease. (p= 0.51). Amongst ECD patients, common (often overlapping) presentations included retroperitoneal or mediastinal fibrosis in 6, exophthalmos secondary to periorbital infiltration in 4 and cerebellar symptoms (ataxia and dysarthria) in 3 patients. Surprisingly, bone involvement was only seen in 36% of the patients. BRAF V600E mutation was positive in 7 (70%) of the 10 patients with available results. Classic nodal involvement was seen in only 8 (42%) of RDD patients and extranodal involvement included subcutaneous masses (n=5), CNS involvement (n=4) and visceral involvement (n=4). Preferred management strategies for unisystem LCH included surgical intervention (n=25), localised radiation (n=4) or “wait and watch” along with smoking cessation (n=14). Systemic cladribine was the given in 15 multisystem LCH patients- 9 received as first line and 6 in subsequent lines. Overall response rates (ORR) after first line of therapy were significantly better in patients with unisystem (76%) compared to multisystem (52%) disease (p=0.049). Twenty (33%) LCH patients required subsequent lines of therapies with four patients receiving targeted therapies (Cobimetinib-3; vemurafenib-1); all these patients attained at least a partial response. Various first line systemic therapies given in ECD were cladribine (n=1), interferon alfa (n=5), anakinra (n=3), vemurafenib (n=1) with ORR of 40%. Eight patients (72%) required subsequent therapies with cladribine in 4, vemurafenib in 2 and dabrafenib and trametinib combination in 2 patients. RDD was managed with systemic steroids in 8 (42%) patients while 4 patients underwent diagnostic surgical excision of the tumour. Concurrent or subsequent hematological malignancies were seen in 3 (5%; included Acute Myeloid Leukemia (AML), Hairy Cell Leukemia (HCL) and JAK2 positive Myeloproliferative Neoplasm (MPN)) LCH patients, 3 ECD patients (CALR mutated MPN, JAK2 positive MPN, Chronic Lymphocytic Leukemia) and 2 RDD patients (AML and MPN). At median follow up of 39.5 months (range 1- 266; IQR-15-96), median Overall Survival (OS) of our cohort was 206 months with 2-year and 5-year OS of 96% and 88% respectively. Although patients with ECD had inferior 5-year OS (79%) compared to patients with LCH (96%) or RDD (86%), it was not statistically significant. (p=0.179) Conclusion: High suspicion is needed in the background of appropriated clinical context since clinical presentation varies widely in adult histiocytic disorders. High incidence of second hematological malignancies in our small cohort warrants more efforts to establish the association between the two entities. Prospective, multicenter studies with molecular discoveries are needed in adult counterpart of this orphan disease.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.005
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.859
Threshold uncertainty score0.284

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.005
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0050.011
Science and technology studies0.0020.001
Scholarly communication0.0020.001
Open science0.0020.002
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.008
GPT teacher head0.212
Teacher spread0.204 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2024
Admission routes2
Has abstractyes

Explore more

Same venueBloodSame topicMast cells and histamineFrench-language works237,207